Bill No. 860, introduced by Senator Weaver and Representative Kannady, amends the Uniform Controlled Dangerous Substances Act by updating the list of substances classified as Schedule I controlled substances. The bill adds several new substances, including various opiates, opium derivatives, hallucinogenic substances, and synthetic cannabinoids, in response to growing concerns about their potential for abuse and harmful effects on public health. It also establishes criteria for including certain substances and provides exemptions for specific industrial uses of compounds like Gamma-Butyrolactone and 1,4 Butanediol, as long as they are properly labeled and marketed to minimize abuse risks.

Additionally, the bill introduces new definitions and classifications for various synthetic compounds, detailing their chemical structures and potential substitutions, including specific types of indoles, amides, esters, and ketones. It specifies that any material containing a prohibited kratom product will also be classified under these new regulations. Importantly, the bill clarifies that any FDA-approved prescription drug will be excluded from Schedule I, aligning state regulations with federal guidelines. The bill is set to take effect on November 1, 2025, following its passage in the Senate on March 25, 2025.